Stocks
Skye Bioscience, Inc.SKYE
NASDAQHealthcareBiotechnology$1.55
Price as of · delayed, not real-time
Skye Bioscience is a clinical-stage biopharmaceutical company developing cannabinoid-based therapies for metabolic and inflammatory diseases. Its lead candidate, SBI-100, is a peripheral CB1 receptor agonist in Phase 2 trials for obesity and metabolic syndrome. Investors track the stock for its potential in the high-demand weight-loss market, though clinical and regulatory risks remain.
52W Range: $1.50-$13.28
Congressional Interest in Skye Bioscience, Inc. (SKYE)
No congressional trades have been disclosed for Skye Bioscience, Inc. (SKYE) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading SKYE?
No congressional trades found for this stock.